Table II.
AUC0–30 (min*nmol/mL) of carvedilol in relation to inhibitor’s concentration, for each tested antidepressant (sertraline, fluvoxamine and bupropion) in rat liver microsomes. Incubations were performed in the control state (no inhibitor), and with varying inhibitors concentrations for 0.5 and 1 μM carvedilol (data presented as mean ± SD, n=3).
| Substrate concentration (μM) | Inhibitor concentration (μM) | Sertraline | Fluvoxamine | Bupropion |
|---|---|---|---|---|
| 1 μM CVD | 0 | 8.2±0.8 | 8.1±1.3 | 8.1±1.3 |
| 0.1 | 14.9±2.2 | 11.2±0.4 | 9.8±1.7 | |
| 0.75 | 24.0±1.5 | 14.4±0.6 | 11.1±0.1 | |
| 1.5 | 23.5±0.2 | 15.7±0.2 | 12.7±1.3 | |
| p* value (ANOVA) | <0.05, S | 0.00001, S | 0.012, S | |
| 0.5 μM CVD | 0 | 2.4±0.1 | 2.2±0.1 | 2.2±0.1 |
| 0.1 | 10.7±1.6 | 4.6±0.3 | 3.3±0.1 | |
| 0.75 | 11.6±1.2 | 6.5±0.2 | 6.6±0.9 | |
| 1.5 | 9.6±0.6 | 7.9±0.2 | 7.2±0.05 | |
| p* value (ANOVA) | 0.0008, S | <0.05, S | 0.00001, S | |
*
ANOVA for intergroup comparison, for each substrate concentration, statistically significant (S) when p < 0.05